Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Xinbo Pharmaceutical Research Co., Ltd. is a prominent Chinese Contract Research Organization (CRO) specializing in preclinical drug safety evaluation and pharmacology. Established in 2010 and headquartered in Dezhou, Shandong, the company provides a wide range of services including toxicology, pharmacokinetics, and medical device evaluation under GLP standards. With nearly 20,000 square meters of laboratory space across sites in Dezhou, Jinan, and Linyi, it holds certifications from the NMPA and is AAALAC accredited. The company has supported the preclinical development of over 500 innovative drugs and 4,800 generic products, covering modalities such as small molecules, biologics, vaccines, and cell therapies. Shandong Xinbo is recognized as a national high-tech enterprise and a Shandong Provincial Gazelle Enterprise, serving a global client base of pharmaceutical companies and research institutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Xinbo Pharmaceutical R&D.